Short interest for Innovative Ind Props gives investors a sense of the degree to which investors are betting on the decline of Innovative Ind Props's stock. Short interest data is updated every two weeks.

Innovative Ind Props Stock (NYSE:IIPR), Short Interest Report

Innovative Ind Props

Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.

Cannabis.DALL.E-AI-

REIT

Real Estate

IIPR

Gain Exposure to Real Estate and Cannabis With This One Stock That Yields 7.7%

Innovative_Industrial_Properties

Long Ideas

News

Markets

Trading Ideas

An investor would need to own $77,357 worth of Innovative Industrial Properties, or 824 shares, to generate a monthly dividend income of $500.

How To Earn $500 A Month From Innovative Industrial Properties Stock

Innovative Industrial Properties, Inc. Common Stock

Innovative Industrial Properties Inc

Innovative Industrial Properties, Inc. 9.00% Series A Cumulative Redeemable Preferred Stock

<p>Xperi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.14) by 64.29 percent. This is a 225 percent decrease over earnings of $0.04 per share from the same period last year.  The company reported quarterly sales of $118.844 million which missed the analyst consensus estimate of $122.111 million by 2.68 percent.  This is a 6.30 percent decrease over sales of $126.839 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

XPER

Xperi Q1 2024 Adj EPS $(0.05) Beats $(0.14) Estimate, Sales $118.844M Miss $122.111M Estimate

<p>MKS Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $0.75 by 57.33 percent. This is a 145.83 percent increase over earnings of $0.48 per share from the same period last year.  The company reported quarterly sales of $868.000 million which beat the analyst consensus estimate of $848.941 million by 2.24 percent.  This is a 9.32 percent increase over sales of $794.000 million the same period last year.</p>


MKSI

MKS Instruments Q1 2024 Adj EPS $1.18 Beats $0.75 Estimate, Sales $868.000M Beat $848.941M Estimate

<p>Genco Shipping &amp; Trading (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNK#NYSE">GNK</a>) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.52 by 15.38 percent.  The company reported quarterly sales of $117.20 million which beat the analyst consensus estimate of $90.74 million by 29.15 percent.  This is a 24.16 percent increase over sales of $94.39 million the same period last year.</p>


Genco Shipping & Trading Q1 2024 Adj EPS $0.44 Misses $0.52 Estimate, Sales $117.20M Beat $90.74M Estimate

<p>Reaffirm the 2024 full-year total revenue guidance in the range of $455 million and $475 million.</p>


Guidance

CPRX

Catalyst Pharmaceuticals Reaffirms FY24 Total Revenue Guidance In The Range Of $455M-$475M Vs $460.53M Est

<p>Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBDC#NYSE">OBDC</a>) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.48 by 2.08 percent.</p>


OBDC

Blue Owl Capital Q1 2024 Adj EPS $0.47 Misses $0.48 Estimate

<p>Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 160 percent decrease over losses of $(0.05) per share from the same period last year.  The company reported quarterly sales of $121.395 million which missed the analyst consensus estimate of $121.410 million by 0.01 percent.  This is a 3.71 percent decrease over sales of $126.077 million the same period last year.</p>


NDLS

Noodles Q1 2024 Adj EPS $(0.13) Beats $(0.17) Estimate, Sales $121.395M Miss $121.410M Estimate

<p>Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.58 by 8.62 percent.  The company reported quarterly sales of $50.361 million which beat the analyst consensus estimate of $47.696 million by 5.59 percent.  This is a 28.21 percent increase over sales of $39.281 million the same period last year.</p>


CCAP

Crescent Capital BDC Q1 NII $0.63 Beats $0.58 Estimate, Sales $50.361M Beat $47.696M Estimate

<p>Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) reported quarterly earnings of $2.10 per share which missed the analyst consensus estimate of $2.12 by 0.94 percent. This is a 2.94 percent increase over earnings of $2.04 per share from the same period last year.  The company reported quarterly sales of $245.744 million which missed the analyst consensus estimate of $260.150 million by 5.54 percent.  This is a 12.66 percent increase over sales of $218.129 million the same period last year.</p>


Chesapeake Utilities Q1 2024 Adj EPS $2.10 Misses $2.12 Estimate, Sales $245.744M Miss $260.150M Estimate

<p>Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) reported quarterly earnings of $0.76 per share which missed the analyst consensus estimate of $0.84 by 9.52 percent.  The company reported quarterly sales of $3.30 billion which beat the analyst consensus estimate of $2.67 billion by 23.42 percent.  This is a 33.35 percent increase over sales of $2.47 billion the same period last year.</p>


Fidelity National Finl Q1 2024 Adj EPS $0.76 Misses $0.84 Estimate, Sales $3.30B Beat $2.67B Estimate

<p>Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 50 percent decrease over earnings of $0.02 per share from the same period last year.  The company reported quarterly sales of $111.153 million which beat the analyst consensus estimate of $109.537 million by 1.48 percent.  This is a 6.02 percent decrease over sales of $118.270 million the same period last year.</p>


PBPB

Potbelly Q1 2024 Adj EPS $0.01 Beats $(0.01) Estimate, Sales $111.153M Beat $109.537M Estimate

<p>Royal Gold (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLD#NASDAQ">RGLD</a>) reported quarterly earnings of $0.91 per share which missed the analyst consensus estimate of $0.94 by 3.19 percent.  The company reported quarterly sales of $148.900 million which missed the analyst consensus estimate of $153.035 million by 2.70 percent.  This is a 12.61 percent decrease over sales of $170.392 million the same period last year.</p>


RGLD

Royal Gold Q1 2024 Adj EPS $0.91 Misses $0.94 Estimate, Sales $148.900M Miss $153.035M Estimate

<p><strong>Full Year 2024 Financial Guidance and Other Financial Notes</strong>:</p>
<ul>
<li>The Company adjusted the top end of our 2024 guidance range and now expects to report Adjusted EBITDA between $207.5 million and $212.5 million for the 2024 fiscal year.</li>
</ul>


ALTG

Alta Equipment Group Adjusted The Top End Of FY24 Guidance Range And Now Expects To Report Adjusted EBITDA Between $207.5M-$212.5M

<p><strong>Beyond Meat Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/05/g38714113/beyond-meat-reports-first-quarter-2024-financial-results">key metrics from the quarter</a>.</p>
<p><strong>Q1 Earnings:</strong> Beyond Meat said first-quarter revenue decreased 18% year-over-year to $75.603 million, which beat&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimates</a>&nbsp;of $75.241 million, per&nbsp;<a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The&nbsp;plant-based meat&nbsp;company reported a first-quarter adjusted loss of 72 cents per share, which missed estimates for a loss of 67 cents per share. </p>
<p>U.S. retail channel net revenues decreased&nbsp;16% year-over-year and U.S. foodservice channel net revenues decreased&nbsp;16.2%. International retail channel net revenues fell 12% and international foodservice channel net revenues decreased&nbsp;28.7%.</p>
<p>Beyond Meat ended the quarter with $173.5 million in cash, cash equivalents and restricted cash.</p>
<p>&#8220;Together with measures we are exploring to bolster our balance sheet, we continue to work to position 2024 as a pivotal year as we strive to achieve sustainable and profitable operations,&#8221; said <strong>Ethan Brown</strong>, president and CEO of Beyond Meat.</p>
<p><strong>Outlook: </strong>Beyond Meat expects second-quarter revenue to be between $85 million and $90 million. The company expects full-year 2024 revenue to be between $315 million and $345 million.</p>
<p>Gross margin is expected to be in the mid to high teens range for the full-year 2024. The company noted that gross margin is expected to be higher in the second half of the year relative to the first half.</p>
<p>&#8220;The company&#8217;s operating environment continues to be affected by uncertainty relating to macroeconomic issues including: ongoing, further weakened demand in the plant-based meat category, inflation and high interest rates and concerns about the likelihood of a recession, among other things, all of which could have unforeseen impacts on the Company&#8217;s actual realized results,&#8221; the company said.</p>
<p>Management will hold a conference call to discuss its quarterly results at 5 p.m. ET.</p>
<p><em>Check This Out: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/05/38708974/stocks-falter-as-fed-signals-need-for-higher-for-longer-rates-uber-crashes-energy-se">Stocks Falter As Fed Signals Need For Higher-For-Longer Rates; Uber Crashes, Energy Sector Loses Ground: What&#8217;s Driving Wednesday&#8217;s Market?</a></em></p>
<p><strong>BYND Price Action: </strong><a href="https://www.benzinga.com/quote/BYND" target="_blank" rel="noreferrer noopener">Beyond Meat shares</a> were down 3.65% after hours at $7.91 at the time of writing, per <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p><em>Photo: courtesy of Beyond Meat.</em></p>


Movers

BYND

Beyond Meat Q1 Earnings: Revenue Beat, EPS Miss, Working To Make 2024 A Pivotal Year And More

CoreCivic Sees FY24 FFO $1.36-$1.46 Vs $1.55 Estimate

<p>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 27.27 percent increase over losses of $(0.22) per share from the same period last year.  The company reported quarterly sales of $388.488 million which beat the analyst consensus estimate of $352.466 million by 10.22 percent.  This is a 28.61 percent increase over sales of $302.077 million the same period last year.</p>


PIII

P3 Health Partners Q1 2024 GAAP EPS $(0.16) Misses $(0.11) Estimate, Sales $388.488M Beat $352.466M Estimate

<p>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.55) by 3.64 percent. This is a 20.83 percent increase over losses of $(0.72) per share from the same period last year.  The company reported quarterly sales of $28.168 million which missed the analyst consensus estimate of $30.341 million by 7.16 percent.  This is a 15.83 percent decrease over sales of $33.467 million the same period last year.</p>


Outset Medical Q1 2024 Adj EPS $(0.57) Misses $(0.55) Estimate, Sales $28.168M Miss $30.341M Estimate

<p><strong>Kohl's's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 18.36% since its last report. The company recently reported that it has <strong>35.40 million shares sold short</strong>, which is 44.62% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 6.37 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715201121_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 9.68%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Looking Into Kohl's's Recent Short Interest

<p><strong>SouthState's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSB#NYSE">SSB</a>) short percent of float has risen 3.02% since its last report. The company recently reported that it has <strong>2.93 million shares sold short</strong>, which is 5.12% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 7.44 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>SouthState Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715201115_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for SouthState has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing SouthState's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SouthState's peer group average for short interest as a percentage of float is 3.58%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into SouthState's Recent Short Interest

<p><strong>ExlService Holdings's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NYSE">EXLS</a>) short percent of float has fallen 13.13% since its last report. The company recently reported that it has <strong>6.29 million shares sold short</strong>, which is 5.36% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.39 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>ExlService Holdings Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715201110_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for ExlService Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing ExlService Holdings's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ExlService Holdings's peer group average for short interest as a percentage of float is 4.93%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


EXLS

(EXLS) - Analyzing ExlService Holdings's Short Interest

<p>Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 32.5 percent increase over losses of $(0.80) per share from the same period last year.  The company reported quarterly sales of $69.222 million which missed the analyst consensus estimate of $70.171 million by 1.35 percent.  This is a 119.07 percent increase over sales of $31.598 million the same period last year.</p>


MIRM

Mirum Pharmaceuticals Q1 2024 GAAP EPS $(0.54) Misses $(0.48) Estimate, Sales $69.222M Miss $70.171M Estimate

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Investors typically seek out very popular stocks with a large trading volume in hopes of riding the wave of growth potential. However, many investors who only pay attention to very popular stocks miss out on significant buying opportunities among&nbsp;stocks traded less often.</p>



<p>Investors should pay attention to a broader array of companies and refrain from avoiding certain stocks because they aren&rsquo;t heavily traded.</p>



<p>These&nbsp;particular&nbsp;stocks have an average trading volume below 500,000, making them fairly obscure&nbsp;in most investors&rsquo; eyes.&nbsp;However, they all offer&nbsp;strong&nbsp;returns and&nbsp;provide investors with&nbsp;huge&nbsp;upside potential.</p>



<h2>Innovative Industrial Properties (IIPR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-7-300x169.jpg" alt="A close-up shot of a marijuana growhouse. cannabis trends"><div>Source: Shutterstock</div></div><p><strong>Innovative Industrial Properties</strong>&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/iipr-stock-quote/"><strong>IIPR</strong></a>) is an industrial REIT company that owns, manages, and leases properties for use within the regulated cannabis industry. It offers a substantial portfolio of over 100 properties in 19 states.</p>



<p>Over the past year, its share price has increased rapidly by 52% due to&nbsp;a number of&nbsp;factors, including a strong dividend, increased revenue growth, and a focus on resolving tenant issues.</p>



<p>IIPR&rsquo;s dividend currently stands at approximately 7.41% on an annual basis, having increased for six consecutive years. Its latest quarterly dividend was one dollar eighty-two cents, paid out to investors on April 15. IIPR offers such a great dividend mainly because, as a real estate investment trust (<a href="https://investorplace.com/stock-quotes/reit-stock-quote/"><strong>REIT</strong></a>), it&nbsp;is required&nbsp;to distribute 90% of its taxable income to investors, primarily in the form of dividends.</p>



<p>On February 26, IIPR announced its&nbsp;<a href="https://investors.innovativeindustrialproperties.com/press-releases/2024/02-26-2024-214913474" target="_blank">earnings for the fourth quarter of the full year 2023</a>, stating that total revenue increased by 12% and net income remained practically unchanged compared to the previous year.</p>



<p>In the past, issues regarding delinquent tenants in 2023 plagued IIPR, which caused investors to flee the company due to its uncertain outlook. However, with its renewed focus on eliminating this issue, IIPR is now at a point where it is collecting 100% of total rent, which has&nbsp;greatly&nbsp;improved investors&rsquo; interest.</p>



<p>IIPR is a solid stock with&nbsp;an abundance of positive traits that&nbsp;investors look for.&nbsp;Its&nbsp;very low&nbsp;average volume is surprising.</p>



<h2>VitTra (VTSI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/small-cap-1600-300x169.png" alt="Small cap displayed on a Wall Street ticker board. Small cap stocks. Small-cap stocks."><div>Source: iQoncept / Shutterstock</div></div><p><strong>VirTra</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vtsi-stock-quote/"><strong>VTSI</strong></a>) is a small-cap industrial company that primarily supplies military and law enforcement with real-world training simulators that are wrap-around screens with varying degrees of total coverage.</p>



<p>Its latest earnings reports positively surprised investors, and its stock price surged by nearly 40% directly following the report. On April 1,&nbsp;its&nbsp;<a href="https://www.virtra.com/virtra-reports-fourth-quarter-and-full-year-2023-financial-results/" target="_blank">fourth quarter full-year 2023</a>&nbsp;earnings were released, stating that total revenue increased by 17%, and net income grew by more than fourfold compared to the previous year.</p>



<p>It has also received a decent&nbsp;<a href="https://seekingalpha.com/news/4090937-virtra-wins-59m-prototype-contract-from-us-army-ivas-prime-contractor-microsoft" target="_blank">contract worth approximately $6 million</a>&nbsp;to provide the U.S. Army with a visual augmentation program.&nbsp;<strong>Microsoft</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/msft-stock-quote/"><strong>MSFT</strong></a>) is the main contractor.</p>



<p>VirTra is an impressive company whose share price has increased by nearly 150% in the last year. It deserves&nbsp;much greater&nbsp;attention from investors and is trading at a considerably decent value.</p>



<h2>Blue Bird (BLBD)</h2>



<div><img width="300" height="199" src="https://investorplace.com/wp-content/uploads/2014/07/43-300x199.jpg" alt=""><div>Source: &copy;iStock.com/kali9</div></div><p><strong>Blue Bird</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/blbd-stock-quote/"><strong>BLBD</strong></a>) is a heavy equipment manufacturer that sells various&nbsp;types of&nbsp;school buses, including gas, diesel, electric, and natural gas-powered.</p>



<p>One this past year, its share price has nearly doubled primarily due to an improvement in overall profitability.&nbsp;</p>



<p>Its most recent earnings release&nbsp;<a href="https://seekingalpha.com/news/4064176-blue-bird-non-gaap-eps-of-0_91-beats-0_58-revenue-of-317_7m-beats-42_57m" target="_blank">beat analysts&rsquo; expectations</a>&nbsp;for revenue and earnings per share. On Febrary 7, Blue Bird reported earnings for the&nbsp;<a href="https://investors.blue-bird.com/news-financial-reporting/press-releases/news-details/2024/Blue-Bird-Reports-Fiscal-2024-FirstQuarter-Record-Results-Raises-2024-Guidance/default.aspx" target="_blank">first quarter of fiscal year 2024</a>, which stated that total revenue increased by 35% year-over-year.&nbsp;A net loss was reported&nbsp;for Q1 FY 2023 of $11 million, and for Q1 FY 2024, that grew to a net income of $26 million. And total unit sales also increased by 8% year-over-year.</p>



<p>Blue Bird improved its earnings guidance for fiscal year 2024 in its latest revision, which stated that total revenue&nbsp;is expected&nbsp;to be between $1.15 and $1.25 billion.</p>



<p>Blue Bird is&nbsp;a great&nbsp;company with&nbsp;strong&nbsp;earnings potential,&nbsp;especially&nbsp;since average unit prices have increased by over 25% and seals continue to grow year-over-year. It&rsquo;s a stock with low volume but impressive potential.</p>



<p><em>As of this writing, Noah Bolton&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Noah has about a year of freelance writing experience. He&rsquo;s worked with Investopedia dealing with
topics such as the stock market and financial news.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/3-obscure-stocks-that-could-revolutionize-your-returns/">3 Obscure Stocks That Could Revolutionize Your Returns</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Obscure Stocks That Could Revolutionize Your Returns

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Sleeper stocks to buy &ndash; based on Nasdaq.com&rsquo;s <a href="https://www.nasdaq.com/glossary/s/sleeper">glossary</a> &ndash; represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot of enterprises so I decided to narrow down the list.</p>



<p>Using TipRanks&rsquo; <a href="https://www.tipranks.com/screener/stocks">Stock Screener</a>, I filtered for ideas that benefit from a series of strong quantitative attributes but simultaneously carry analyst consensus hold ratings. In other words, these are ideas that, by the numbers, should benefit from Wall Street&rsquo;s spotlight. Instead, they&rsquo;re languishing in the background.</p>



<p>Typically, though, the fundamentals find a way of rising to the top. With that, below are compelling sleeper stocks to buy.</p>



<h2>GSK (GSK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/gsk-stock-1-300x169.jpg" alt="A GlaxoSmithKline (GSK) office in London."><div>Source: Willy Barton / Shutterstock.com</div></div><p>A British multinational pharmaceutical and biotechnology company, <strong>GSK</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/"><strong>GSK</strong></a>) represents one of the underlying sector&rsquo;s top enterprises. It enjoys <a href="https://www.gurufocus.com/stock/GSK/summary?search=gsk">stellar operational stats</a>, with margins across the board ranking in the upper echelon. Further, the company&rsquo;s return on equity (ROE) clocks in at 40%, better than 96.5% of the drug manufacturing industry.</p>



<p>Despite the enviable attributes, analysts rate shares a <a href="https://www.tipranks.com/stocks/gsk">consensus hold</a> with no price target listed. Further, the most recent individual rating was a &ldquo;sell&rdquo; from Bank of America. That&rsquo;s not exactly an encouraging dynamic. Nevertheless, GSK could be one of the sleeper stocks to buy.</p>



<p>For one thing, outside of a miss in the fourth quarter last year, GSK has consistently beaten its bottom-line targets for fiscal 2023. Even with the aforementioned miss, the average quarterly surprise comes out to 7.08%.</p>



<p>For the current fiscal year, covering experts believe revenue can reach $39.31 billion, up 4.2% from last year&rsquo;s haul of $37.7 billion. Combined with a 3.53% forward annual dividend yield, GSK brings a balanced investment to the table.</p>



<h2>Dominion Energy (D)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/d-stock-300x169.jpg" alt="a truck bearing the Dominion Energy logo"><div>Source: ying / Shutterstock.com</div></div><p>An energy producer and distributor, <strong>Dominion Energy</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/d-stock-quote/"><strong>D</strong></a>) has three operating segments. Most of the business involves the generation, transmission and distribution of regulated electricity to millions of residential, commercial, industrial and government customers in Virginia, North Carolina and South Carolina. It also is involved in nonregulated long-term contracted renewable electric generation.</p>



<p>Analysts don&rsquo;t care for Dominion, let me just put it out there. Not only do they rate shares a hold, but the <a href="https://www.tipranks.com/stocks/d/forecast">average price target sits at $48.38</a>, implying downside risk. Still, what I appreciate about Dominion is that as a utility player, it enjoys a natural monopoly. Would-be competitors don&rsquo;t even bother due to the entrenchment of the old guard.</p>



<p>What&rsquo;s also really interesting is that analysts believe that the company can post revenue of $16.3 billion by the end of fiscal 2024. If so, that would be up 13.3% from last year&rsquo;s tally of $14.39 billion. Further, the most optimistic sales target calls for $19.87 billion. D stock could be worth a rethink regarding sleeper stocks to buy.</p>



<h2>Innovative Industrial Properties (IIPR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/shutterstock_1414790303-300x169.jpg" alt="Marijuana penny stocks Cannabis leaf on dollar bill. Cannabis Stocks"><div>Source: Shutterstock </div></div><p>Structured as a real estate investment trust or REIT, <strong>Innovative Industrial Properties</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/iipr-stock-quote/"><strong>IIPR</strong></a>) makes for an interesting case for sleeper stocks to buy. <a href="https://innovativeindustrialproperties.com">Per its website</a>, Innovative Industrial is the leading provider of real estate capital for the regulated cannabis industry. It also features a broad portfolio of real estate leased to state-licensed cannabis operators.</p>



<p>Increasingly, the American public has <a href="https://investorplace.com/2024/03/why-does-canopy-growth-cgc-stock-keep-climbing-this-week/">gravitated toward federal legalization of marijuana</a>. That&rsquo;s a far cry from generations ago when the much-maligned plant represented a gateway to other nefarious activities. Also, cannabis could be a major issue in the upcoming presidential election. With the Republicans running a law-and-order message, the Democrats potentially have an opening with prospective voters.</p>



<p>Fundamentally, IIPR could rise from broader cannabis acceptance, especially amid <a href="https://www.nbcnews.com/politics/joe-biden/biden-administration-plans-reclassify-marijuana-easing-restrictions-na-rcna149424">the latest rescheduling news</a>. For a while, the Wall Street suits were skeptical but this dynamic may now shift quite dramatically. Analysts on paper are anticipating earnings per share to reach $5.93 on sales of $321.48 million for this fiscal year. That&rsquo;s up from last year&rsquo;s results of $5.77 EPS on revenue of $309.51 million.</p>



<p>However, the latest rumblings may change everything. IIPR is one of the sleeper stocks but the market is waking up to it.</p>



<h2>Organon (OGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600-300x169.jpg" alt="Nurse holding a tablet with icons representing different aspects of healthcare and healthcare data representing CANO stock. Healthcare Tech Stocks"><div>Source: metamorworks / Shutterstock</div></div><p>Operating in the drug manufacturing industry, <strong>Organon</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ogn-stock-quote/"><strong>OGN</strong></a>) develops and delivers solutions via a portfolio of prescription therapies and medical devices targeting women&rsquo;s health. Its portfolio consists of various products such as contraception and fertility brands. It also provides therapeutics addressing conditions such as <a href="https://finance.yahoo.com/quote/OGN/">uterine bleeding and hypertension</a>.</p>



<p>Fundamentally, OGN makes a case for sleeper stocks to buy due to the projected growth in the global women&rsquo;s health market. Per Grand View Research, this sector <a href="https://www.grandviewresearch.com/industry-analysis/womens-health-market">reached a valuation of $44.36 billion</a> last year. By 2030, the sector could expand to $67.07 billion, representing a compound annual growth rate of 5.7%.</p>



<p>For the current fiscal year, analysts anticipate EPS to reach $4.26 on revenue of $6.37 billion. Last year, the company posted EPS of $4.14 on sales of $6.26 billion. Organon also pays a forward dividend yield of 5.93%, which must be factored into the equation.</p>



<p>Lastly, shares are undervalued, trading at only 4.65X trailing-year earnings and only 0.77X trailing-year revenue. For a reliable idea, OGN may be one of the sleeper stocks to buy.</p>



<h2>Affirm (AFRM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/afrm_affirm1600-300x169.png" alt="Smartphone with website of US financial technology company Affirm Holdings Inc (AFRM) on screen with logo Focus on top-left of phone display"><div>Source: Wirestock Creators / Shutterstock.com</div></div><p>Falling under the infrastructure software ecosystem, <strong>Affirm</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/afrm-stock-quote/"><strong>AFRM</strong></a>) operates a platform for digital and mobile-first commerce. <a href="https://finance.yahoo.com/quote/AFRM/profile">Per its corporate profile</a>, Affirm&rsquo;s platform includes point-of-sale payment solutions for consumers, merchant commerce solutions, and a consumer-focused app. It&rsquo;s perhaps best known for its buy now, pay later (BNPL) app.</p>



<p>Fundamentally, the case of AFRM representing one of the sleeper stocks to buy comes down to the <a href="https://www.bankrate.com/loans/personal-loans/buy-now-pay-later-survey/#:~:text=Over%20half%20of%20millennials%20have%20used%20BNPL%20services%2C%20compared%20to,saying%20they've%20used%20it.">addressable market</a>. Per Bankrate, &ldquo;[o]ver half of millennials have used BNPL services, compared to 1 in 4 boomers. Unsurprisingly, buy now, pay later is more widely adopted among younger Americans, with 55 percent of millennials and 51 percent of Gen Zers saying they&rsquo;ve used it.&rdquo;</p>



<p>Even better, analysts anticipate big growth for Affirm in fiscal 2024, targeting revenue of $2.21 billion. If so, that would come out to a 39.2% increase from last year&rsquo;s print of $1.59 billion. In the following year, covering experts anticipate sales of $2.67 billion, up 20.9% from projected 2024 sales.</p>



<p>It&rsquo;s a risky argument given the pressures of the consumer economy. Still, if you want to speculate, AFRM could be an intriguing idea.</p>



<h2>Kaiser Aluminum (KALU)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/04/aluminum-300x169.jpg" alt="a roll of aluminum in a factory"><div>Source: Shutterstock</div></div><p>Working in the basic materials industry, <strong>Kaiser Aluminum</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kalu-stock-quote/"><strong>KALU</strong></a>) presents another high-risk, high-reward case for sleeper stocks to buy. Together with its subsidiaries, Kaiser &ndash; <a href="https://finance.yahoo.com/quote/KALU/profile">according to its public profile</a> &ndash; engages in the manufacture and sale of semi-fabricated specialty aluminum mill products in the U.S. and internationally. Its main industries are aerospace and defense, aluminum beverage and food packaging and automotive.</p>



<p>Like Affirm, Kaiser &ndash; while obviously working in a completely different industry &ndash; is highly dependent on the consumer economy. While broader geopolitical considerations may drive the defense sector, other industries which Kaiser serves, such as automotive, require consumer confidence. That&rsquo;s what makes KALU ambiguous and that&rsquo;s reflected in recent volatility.</p>



<p>However, it&rsquo;s also fair to point out that while fiscal 2024 may be a wash in terms of growth, fiscal 2025 could be a different story. That&rsquo;s when analysts are projecting revenue to reach $3.4 billion, up 9.4% from projected 2024 sales of $3.1 billion.</p>



<p>At the same time, EPS could skyrocket to $7.53. If so, KALU could be a surprising idea among sleeper stocks to buy.</p>



<h2>Sunoco (SUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/01/sun1600sunstock-300x169.jpg" alt="Image of a Sunoco gas station in Orlando, Florida"><div>Source: Alex Pesantes / Shutterstock</div></div><p>An energy player, <strong>Sunoco</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/sun-stock-quote/"><strong>SUN</strong></a>) specializes in the oil and gas refining and marketing sector. <a href="https://finance.yahoo.com/quote/SUN/profile">According to its corporate profile</a>, Sunoco distributes and retails motor fuels in the U.S. It operates through two segments: Fuel Distribution and Marketing and All Other. It&rsquo;s the former category &ndash; the downstream business &ndash; that could be quite enticing.</p>



<p>Yes, Sunoco has been choppy recently. With uncertainty clouding the economic landscape, energy demand has a question mark around it. However, such inquiries should fade soon. Cynically speaking, the world continues to run on oil. Further, the fallout in the electric vehicle space means that people are still overwhelmingly dependent on petroleum products.</p>



<p>It&rsquo;s interesting that for fiscal 2024, analysts see Sunoco generating EPS of $6.21. That&rsquo;s a dramatic lift from last year&rsquo;s EPS of $3.65. Given the geopolitical backdrop and the possible pressures to supply, the projected profitability spike isn&rsquo;t surprising.</p>



<p>However, revenue could also rise, especially if laid-off workers start job hunting. Further, a gradual fading of work-from-home privileges could lift demand. Thus, the trailing-year sales multiple of 0.21X is very low.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-sleeper-stocks-to-buy-before-wall-street-wakes-up-april-2024/">7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024

16 out of 20 S&P 500 real estate stocks post earnings beat - Earnings Scorecard

Innovative Industrial Properties: We're Not Ready To Reclassify

Cannabis Continues Powering To Big Gains With Historic DEA Rescheduling

13 Fast-Growing REITs With Strong Balance Sheets

Real estate stocks outperform major market averages as rate hikes are ruled out, earnings continue to grow

The Labor Downshift

Piper Sandler analyst Alexander Goldfarb assigned a Hold rating to Innovative Industrial Properties (IIPR – Research Report) today and set a price ...

Piper Sandler Releases a Hold Rating on Innovative Industrial Properties (IIPR)

19 REITs estimated to increase dividend in Q2, says report

AAWH

AFCG

AFRM

AYRWF

AYWWF

BBRE

BEKE

BLBD

BRSP

CBRE

CHCT

COLD

CRLBF

CSGP

CTRE

CUBE

CURLF

DFAR

DOUG

EPRT

EQIX

FBRT

FREL

GHBWF

GLASF

GTBIF

HOMZ

ILPT

INDS

INVH

JPRE

KALU

KBWY

LAMR

LAND

MAPS

MAPSW

MDRR

MITT

MORT

MSFT

MSOS

NETL

NLCP

NREF

NTST

NURE

NXRT

NYMT

PGRE

PPTY

REET

REXR

RIET

RITM

ROOF

RSPR

SAFE

SBAC

SCHH

SEVN

SPRE

SRET

SRVR

TCNNF

TRNO

TRTX

UNIT

USRT

VICI

VNQI

VRAI

VRNOF

VTSI

WELL

XLRE

Contracts

Small Cap

Press Releases

UC Asset Signed MOU with Tenant to Build 8000 sq ft Cannabis Property

Innovative Industrial Properties to Report 2023 Third Quarter Results

Innovative Industrial Properties Reports Third Quarter 2023 Results

Innovative Industrial Properties Declares Fourth Quarter 2023 Dividends

Innovative Industrial Properties Announces Tax Treatment of 2023 Distributions

Innovative Industrial Properties to Report 2023 Fourth Quarter and Year-End Results

Innovative Industrial Properties Reports Fourth Quarter and Full-Year 2023 Results

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Innovative Ind Props Stock (NYSE:IIPR), Short Interest Report

People Also Watch